GW Pharmaceuticals PLC GW Research and Development Day Details (8428S)
September 29 2014 - 8:00AM
UK Regulatory
TIDMGWP
RNS Number : 8428S
GW Pharmaceuticals PLC
29 September 2014
GW Pharmaceuticals Research and Development Day Details
London, UK, 29 September 2014: GW Pharmaceuticals plc (Nasdaq:
GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform, provided the following details regarding its
upcoming Research and Development Day scheduled for 14 October,
2014:
Location: New York City
Date: 14 October, 2014
Time: Registration begins at 9:30 a.m. ET, program from 10:00
a.m. ET - 1:00 p.m. ET
Agenda: The program will provide an update on GW's product
pipeline and is expected to include presentations on the science
and application of cannabinoids, updated data from the Epidiolex(R)
epilepsy expanded access program, and a review of current pipeline
programs including initial data from GW's ulcerative colitis Phase
2a clinical trial.
In addition to GW presenters, guest speakers will include:
Dr. Vincenzo Di Marzo, Director of the Institute of Biomolecular
Chemistry of the National Research Council (ICB-CNR) in Naples,
Italy and one of the world's leading cannabinoid scientists
Dr. Elizabeth Thiele, Director of the Pediatric Epilepsy Program
at Massachusetts General Hospital and Harvard Professor of
Neurology
Dr. Orrin Devinsky, Director the NYU Comprehensive Epilepsy
Center and Professor of Neurology, Neurosurgery and Psychiatry at
the NYU School of Medicine
Attendees are requested to RSVP to Stephen Schultz, Vice
President of Investor Relations. A live audio webcast of the
presentation will be available through GW's corporate website in
the investor relations section from the investor's calendar of
events page at www.gwpharm.com. A replay will be available soon
after the live presentation.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform in a broad range of
disease areas. GW commercialized the world's first plant-derived
cannabinoid prescription drug, Sativex(R), which is approved for
the treatment of spasticity due to multiple sclerosis in 26
countries outside the United States. Sativex is also in Phase 3
clinical development as a potential treatment of pain associated
with advanced cancer. This Phase 3 program has received Fast Track
Designation from the U.S. Food and Drug Administration (FDA) and is
intended to support the submission of a New Drug Application for
Sativex in cancer pain with the FDA and in other markets around the
world. GW has a deep pipeline of additional cannabinoid product
candidates, including Epidiolex(R) in the treatment of childhood
epilepsy, which has received Fast Track Designation from the FDA
for Dravet syndrome as well as Orphan Drug Designations from the
FDA in both the treatment of Dravet syndrome and Lennox-Gastaut
syndrome. GW's product pipeline also includes compounds in Phase 1
and 2 clinical development for glioma, ulcerative colitis, type 2
diabetes, and schizophrenia. For further information, please visit
www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc (Today) + 44 20 3727 1000
Justin Gover, Chief Executive Officer (Thereafter) + 44 1980
557000
Stephen Schultz, VP Investor Relations 917 280 2424 / 401 500
(U.S.) 6570
FTI Consulting (Media Enquiries)
Ben Atwell / Simon Conway / John Dineen
(UK) + 44 20 3727 1000
Robert Stanislaro (U.S.) 212 850 5657
Trout Group, LLC (U.S. investor relations)
Todd James / Chad Rubin 646 378 2900
Peel Hunt LLP (UK NOMAD) +44 20 7418 8900
James Steel / Clare Terlouw
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCKMGZLRLGGDZG
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024